

### AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of claims in the application.

1. (Currently Amended) A wound dressing for accelerating epidermal regeneration which comprises:

at least one polypeptide (P) ~~having at least one species of epidermal regeneration-  
accelerating minimal amino acid sequences (X) selected from the group consisting of Arg-Gly-  
Asp (SEQ ID NO: 1), Ile-Lys-Val-Ala-Val (SEQ ID NO: 2), and Tyr-Ile-Gly-Ser-Arg (SEQ ID  
NO: 3), and at least one auxiliary amino acid sequence (Y),~~

a polyalkylenepolyamine and/or polyarylenepolyamine (A) having a weight average  
molecular weight of 2,000 to 60,000, and

a sheet (S) being polyurethane,

wherein the at least one polypeptide (P) is selected from the group consisting of:

(1) a polypeptide having 13 Arg Gly Asp sequences (SEQ ID NO: 1) and 13 (Gly  
Ala Gly Ala Gly Ser)<sub>9</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>9</sub>) chemically bonded  
to each other in an alternating fashion,

(2) a polypeptide having 5 Arg Gly Asp sequences (SEQ ID NO: 1) and 5 (Gly  
Ala Gly Ala Gly Ser)<sub>3</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>3</sub>) chemically bonded to  
each other in an alternating fashion,

(3) a polypeptide having 3 Arg Gly Asp sequences (SEQ ID NO: 1) and 3 (Gly  
Val Pro Gly Val)<sub>2</sub> Gly Gly (Gly Ala Gly Ala Gly Ser)<sub>3</sub> sequences((residues 1-30 of SEQ  
ID NO: 49)<sub>9</sub> chemically bonded to each other in an alternating fashion,

(4) a polypeptide having 13 Ile-Lys-Val-Ala-Val sequences (SEQ ID NO: 2) and 13 (Gly Ala Gly Ala Gly Ser)<sub>9</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>9</sub>) chemically bonded to each other in an alternating fashion,

(5) a polypeptide having 5 Ile-Lys-Val-Ala-Val sequences (SEQ ID NO: 2) and 5 (Gly Ala Gly Ala Gly Ser)<sub>3</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>3</sub>) chemically bonded to each other in an alternating fashion,

(6) a polypeptide having 3 Ile-Lys-Val-Ala-Val sequences (SEQ ID NO: 2) and 3 (Gly Val Pro Gly Val)<sub>2</sub> Gly Gly (Gly Ala Gly Ala Gly Ser)<sub>3</sub> sequences((residues 1-30 of SEQ ID NO: 49)<sub>9</sub> chemically bonded to each other in an alternating fashion,

(7) a polypeptide having 13 Tyr-Ile-Gly-Ser-Arg sequences (SEQ ID NO: 3) and 13 (Gly Ala Gly Ala Gly Ser)<sub>9</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>9</sub>) chemically bonded to each other in an alternating fashion,

(8) a polypeptide having 5 Tyr-Ile-Gly-Ser-Arg sequences (SEQ ID NO: 3) and 5 (Gly Ala Gly Ala Gly Ser)<sub>3</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>3</sub>) chemically bonded to each other in an alternating fashion, and

(9) a polypeptide having 3 Tyr-Ile-Gly-Ser-Arg sequences (SEQ ID NO: 3) and 3 (Gly Val Pro Gly Val)<sub>2</sub> Gly Gly (Gly Ala Gly Ala Gly Ser)<sub>3</sub> sequences((residues 1-30 of SEQ ID NO: 49)<sub>9</sub> chemically bonded to each other in an alternating fashion,

wherein the at least one polypeptide (P) and the sheet (S) are bonded by a covalent bonding,~~and~~

~~wherein said auxiliary amino acid sequence (Y) is selected from the group consisting of:~~

~~(Gly Ala)<sub>a</sub>((residues 1-2 of SEQ ID NO: 4)<sub>a</sub>),~~  
~~(Gly Ala-Gly Ala-Gly Ser)<sub>b</sub>((residues 1-6 of SEQ ID NO: 7)<sub>b</sub>),~~  
~~(Gly Ala-Gly Ala-Gly Tyr)<sub>e</sub>((residues 1-6 of SEQ ID NO: 10)<sub>e</sub>),~~  
~~(Gly Ala-Gly Val-Gly Tyr)<sub>d</sub>((residues 1-6 of SEQ ID NO: 13)<sub>d</sub>),~~  
~~(Gly Ala-Gly Tyr-Gly Val)<sub>e</sub>((residues 1-6 of SEQ ID NO: 16)<sub>e</sub>),~~  
~~{Asp-Gly-Gly (Ala)<sub>f</sub>-Gly-Gly-Ala}<sub>g</sub>((residues 1-12 of SEQ ID NO: 19)<sub>g</sub>),~~  
~~(Gly-Val-Pro-Gly-Val)<sub>h</sub>((residues 1-5 of SEQ ID NO: 22)<sub>h</sub>),~~  
~~(Gly)<sub>i</sub>((residue 1 of SEQ ID NO: 25)<sub>i</sub>),~~  
~~(Ala)<sub>j</sub>((residue 1 of SEQ ID NO: 28)<sub>j</sub>),~~  
~~(Gly-Gly-Ala)<sub>k</sub>((residues 1-3 of SEQ ID NO: 31)<sub>k</sub>),~~  
~~(Gly-Val-Gly-Val-Pro)<sub>m</sub>((residues 1-5 of SEQ ID NO: 34)<sub>m</sub>),~~  
~~(Gly-Pro-Pro)<sub>n</sub>((residues 1-3 of SEQ ID NO: 37)<sub>n</sub>),~~  
~~(Gly-Ala-Gln-Gly-Pro-Ala-Gly-Pro-Gly)<sub>o</sub>((residues 1-9 of SEQ ID NO: 40)<sub>o</sub>),~~  
~~(Gly-Ala-Pro-Gly-Ala-Pro-Gly-Ser-Gln-Gly-Ala-Pro-Gly-Leu-Gln)<sub>p</sub>((residues 1-15 of SEQ ID NO: 43)<sub>p</sub>), and~~  
~~(Gly-Ala-Pro-Gly-Thr-Pro-Gly-Pro-Gln-Gly-Leu-Pro-Gly-Ser-Pro)<sub>q</sub>((residues 1-15 of SEQ ID NO: 46)<sub>q</sub>),~~

~~wherein a is an integer from 5 to 100; b, c, d, and e each are an integer from 2 to 33; f is an integer from 1 to 194; g is an integer from 1 to {200/(6 + f)} with any fraction omitted; h is an integer from 2 to 40; i and j each are an integer from 10 to 200; k is an~~

~~integer from 3 to 66; m is an integer from 2 to 40; n is an integer from 3 to 66; o is an integer from 1 to 22; and p and q each are an integer from 1 to 13.~~

2-6. (Cancelled)

7. (Original) The wound dressing according to Claim 1

wherein the polyalkylenepolyamine and/or polyarylenepolyamine (A) is a polyethyleneimine.

8. (Withdrawn) A method for epidermal regeneration treatment which comprises using the wound dressing according to Claim 1.

9-13. (Cancelled)

14. (Currently Amended) The wound dressing according to claim 1 [[13]], wherein the at least one polypeptide (P) is selected from the group consisting of ~~ProNectin F and ProNectin L~~

the polypeptide having 13 Arg Gly Asp sequences (SEQ ID NO: 1) and 13 (Gly Ala Gly Ala Gly Ser)<sub>9</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>9</sub>) chemically bonded to each other in an alternating fashion, and

Application No.: 10/797,606  
Art Unit: 1654

Amendment  
Attorney Docket No.: 042190

the polypeptide having 13 Ile-Lys-Val-Ala-Val sequences (SEQ ID NO: 2) and 13 (Gly Ala Gly Ala Gly Ser)<sub>9</sub> sequences ((residues 1-6 of SEQ ID NO: 7)<sub>9</sub>) chemically bonded to each other in an alternating fashion.